Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland

Abstract

Introduction: Currently, 15-20% of individuals with coronary artery disease (chronic coronary syndrome [CCS]) or peripheral artery disease (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3-4 years. Using PICOSTEPS (Patients-Intervention-Comparators-Outcomes-Setting-Time-Effects-Perspective-Sensitivity analysis) reporting, we evaluated the cost-effectiveness of recently approved rivaroxaban 2.5 mg twice daily in combination with acetylsalicylic acid 100 mg Digital Features To view digital features for this article go to

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease

“…In this study, we observed the cost-effectiveness of the three treatments at different dosing lengths by varying the cycle. The ICER per QALY gained for the rivaroxaban plus aspirin group decreases over time, as has been widely demonstrated in studies in other countries and regions ( Zomer et al, 2019 ; Soini et al, 2020 ; Lee et al, 2021 ). This suggests that the use of rivaroxaban plus aspirin therapy as a long-term secondary prevention drug for stable CVDs would be more cost-effective.…”

“…the COMPASS trial currently provides the highest level of evidence on the efficacy of rivaroxaban plus aspirin for secondary prevention of CVD. The use of data from the COMPASS trial as parameters for a Markov model makes this study highly representative of the target population ( de Jong et al, 2019 ; Zomer et al, 2019 ; Soini et al, 2020 ). Low-does rivaroxaban plus aspirin therapy is cost-effective in preventing adverse cardiovascular events compared with aspirin alone in high-income countries.…”